ERBA Diagnostics, Inc. (fka ERBA)

[Pheman]

Anyone have any info on a liquidating payment made in September?

[Renee]

ERBA registration revoked:

https://www.sec.gov/litigation/admin/2020/34-89695.pdf

[clearsudden]

Whoever is the puppet master of this needs to be in cuffs ASAP

[Renee]

ERBA SEC Suspension for severely delinquent Financials:

https://www.sec.gov/litigation/suspensions/2020/34-89207.pdf

Order:

https://www.sec.gov/litigation/suspensions/2020/34-89207-o.pdf

Admin. Proceeding:

https://www.sec.gov/litigation/admin/2020/34-89208.pdf

[ALERTS100%to10000%GAIN]

ERBA from 8k will bank $21,750,000 dollars ,you kidding me trading .265 now

[ALERTS100%to10000%GAIN]

ERBA .0023/.0025 will run crazy here,~~On June 17, 2019, Diamedix Corporation, a wholly-owned subsidiary of ERBA Diagnostics, Inc., as seller (“ Diamedix ”), entered into a Purchase and Sale Agreement (the “ Agreement ”) with PRH Investments, LLC, as buyer (“ Buyer ”), for the sale of the real property owned by Diamedix located at 2115, 2127, 2140, 2141, 2150, 2160 North Miami Avenue, 2155 NW Miami Court and 38 NW 22 nd Street, in Miami, Florida, and all improvements thereon (collectively, the “ Property ”).



Purchase Price . The purchase price for the Property is $21,750,000 (the “ Purchase Price ”).

[ALERTS100%to10000%GAIN]

ERBA~~Purchase Price . The purchase price for the Property is $21,750,000 (the “ Purchase Price ”).

[ALERTS100%to10000%GAIN]

ERBA~~On June 17, 2019, Diamedix Corporation, a wholly-owned subsidiary of ERBA Diagnostics, Inc., as seller (“ Diamedix ”), entered into a Purchase and Sale Agreement (the “ Agreement ”) with PRH Investments, LLC, as buyer (“ Buyer ”), for the sale of the real property owned by Diamedix located at 2115, 2127, 2140, 2141, 2150, 2160 North Miami Avenue, 2155 NW Miami Court and 38 NW 22 nd Street, in Miami, Florida, and all improvements thereon (collectively, the “ Property ”).



Purchase Price . The purchase price for the Property is $21,750,000 (the “ Purchase Price ”).

[ALERTS100%to10000%GAIN]

ERBA~~HUGEEE 8K Item 1.01 Entry into a Material Definitive Agreement.



On June 17, 2019, Diamedix Corporation, a wholly-owned subsidiary of ERBA Diagnostics, Inc., as seller (“ Diamedix ”), entered into a Purchase and Sale Agreement (the “ Agreement ”) with PRH Investments, LLC, as buyer (“ Buyer ”), for the sale of the real property owned by Diamedix located at 2115, 2127, 2140, 2141, 2150, 2160 North Miami Avenue, 2155 NW Miami Court and 38 NW 22 nd Street, in Miami, Florida, and all improvements thereon (collectively, the “ Property ”).



Purchase Price . The purchase price for the Property is $21,750,000 (the “ Purchase Price ”).



Survey Review Period . The Agreement provides a 14 day survey period (the “ Survey Review Period ”) during which Buyer has the right to review a current ALTA/NSPS survey of the Property and confirm the square footage of the Property. If the Survey reflects that the Property contains less than a certain square footage, then Buyer may terminate the Agreement by providing written notice on or before expiration of the Survey Review Period (such notice, the “ Survey Termination Notice ”). To the extent that the Agreement is not terminated prior to the expiration of the Survey Review Period, Buyer has the right to record a Memorandum of Contract against the Property pursuant to which third parties are put on notice of the existence of the Agreement and Buyer is given the right to record a claim of lien against the Property if Diamedix fails to return the Earnest Money (or any portion thereof) as required pursuant to the Agreement.



Examination Period . The Agreement provides for a 60 day examination period (the “ Examination Period ”) during which Buyer has the right to conduct a due diligence investigation of the Property and terminate the Agreement in its sole and absolute discretion. While the Agreement is binding upon Diamedix, Buyer, in its sole and absolute discretion, may terminate the Agreement during the Examination Period.



Anticipated Closing Date . The Agreement provides for the consummation of the purchase and sale of the Property to occur within 60 days after the expiration of the Examination Period.



Earnest Money . Upon entering into the Agreement, Buyer will place into escrow the sum of $100,000 (the “ Initial Earnest Money Deposit ”), and, upon the expiration of the Examination Period, Buyer will deliver to Diamedix the sum of $400,000 (the “ Additional Earnest Money Deposit ,” together with the Initial Earnest Money Deposit, collectively, the “ Earnest Money ”). If Buyer terminates the Agreement during the Survey Review Period by providing a Survey Termination Notice, then the Initial Earnest Money Deposit will be returned to Buyer. If the Survey reflects that the Property contains more than a certain square footage or if Buyer fails to timely deliver a Survey Termination Notice prior to the expiration of the Survey Review Period, then the Escrow Agent will deliver to Diamedix the Initial Earnest Money Deposit. If Buyer terminates the Agreement after the expiration of the Survey Review Period, but prior to the expiration of the Examination Period, then the Initial Earnest Money Deposit will be retained by Diamedix. Once any portion of the Earnest Money is delivered to Diamedix, Diamedix is not required to hold the Earnest Money in escrow and such Earnest Money may be utilized by Diamedix for any purpose and without restriction, subject however, to Diamedix’s obligation to return the Earnest Money following a termination of the Agreement pursuant to certain terms of the Agreement.



Defaults . In the event of a default under the Agreement by Buyer, Diamedix would be entitled to terminate the Agreement and retain the Earnest Money as its sole remedy. In the event of a default under the Agreement by Diamedix, Buyer would be entitled to: (i) terminate the Agreement and receive a refund of the Initial Earnest Money Deposit and/or Additional Earnest Money Deposit, as applicable, together with a reimbursement from Diamedix of Buyer’s documented third party transaction costs and expenses up to $75,000; (ii) attempt to specifically enforce the performance by Diamedix of its obligations under the Agreement; or (iii) only if the remedy of specific performance is not available to Buyer as a result of an intentional act on the part of Diamedix, then Buyer may pursue an action against Diamedix for Buyer’s actual damages.



Reimbursement of Certain Costs . In connection with the demolition of certain improvements located on the Property in accordance with the terms of the Agreement, Buyer has agreed to reimburse Diamedix for any costs and/or expenses incurred by Diamedix in connection with such demolition in excess of $100,000.







Assignment . The Agreement may be assigned by Buyer to any entity in which Buyer or its principals have a controlling interest without the consent of Diamedix.



Certain Other Provisions . The Agreement contains other representations, warranties, conditions, covenants and agreements that the Company believes are customary for transactions of this type.



The foregoing description of the Agreement set forth under this Item 1.01 does not purport to be complete. Such description is only a summary and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated into this Item 1.01 in its entirety.



As of March 31, 2019, the net book value of the land, buildings and improvements being sold was $352,957.



Safe Harbor Statement



Except for the historical matters contained herein, statements in this Current Report on Form 8-K are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be preceded by, followed by or otherwise include the words “may,” “will,” “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “could,” “would,” “should,” or similar expressions or statements that certain events or conditions may occur. These forward-looking statements are based largely on ERBA Diagnostics, Inc.’s expectations and the beliefs and assumptions of ERBA Diagnostics, Inc.’s management and on the information currently available to it and are subject to a number of risks and uncertainties, including, but not limited to, the risks and uncertainties that:




?

Buyer may terminate the Agreement during the 14 day Survey Review Period;




?

Buyer, in its sole and absolute discretion, may terminate the Agreement during the 60 day Examination Period;




?

the consummation of the purchase and sale of the Property may not occur when anticipated, or at all; and




?

other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.



Many of these factors are beyond the control of ERBA Diagnostics, Inc. See also the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC for further discussion of certain risks and uncertainties that could materially and adversely affect the Company’s business, operating results or financial condition.



Item 9.01 Financial Statements and Exhibits.




(d)

Exhibit 10.1 – Purchase and Sale Agreement, dated as of June 17, 2019, by and between Diamedix Corporation and PRH Investments, LLC.

[Helter Skelter]

ERBA Balance Sheet

June 30, 2015. Stockholders' Equity > $16,484,472

OS was 44,086,009 as of August 4, 2015. Current pps is 25 cents.

That gives ERBA a market cap of $11,021,502. That's 2/3rds the Stockholders' Equity (total assets - total liabilities).

Revenues are around $24 million per year...lost $505,178 for that Q.

Need to file. What the hell's wrong with them?



Link > ERBA 10Q PERIOD ENDING JUNE 30, 2015

[clearsudden]

Yes it got delisted too

[Roland Rick Perry]

Dang.

Company has received written and verbal proposals from various potential successor firms, which proposals generally estimate a timeframe of approximately four to eight months to complete the work to allow the Company to file the Reports and the prior financial statements that the Company has previously reported its intention to restate.

Accordingly, the Company has determined that it will not be able to file the Reports and regain compliance with the continued listing standards of the Company Guide by November 25, 2016.

[willlbone]

Thinking 10 cents.

[Renee]

ERB changed to ERBA. Delisted from the AMEX to the OTC:

http://otce.finra.org/DLAdditions

[akamaii]

Out no volume at all. Should go up once the Ceo decides to be current with filings etc glta

[akamaii]

Anyways the diagnostic sector is consolidating co I work for just bought a diagnostic co for 4billion a week ago or two and the yesterday a diagnostic co I follow hit 52 week high. From a chart perspective erb hit 52 week lows twice this last time on high volume pop. This should be the last low for now. It seems to be consolidating the recent pop and move upwards hopefully the co brings out some news etc. the co is real and a x coworker that worked with me works there at erb

[clearsudden]

There's not much of a discussion
I followed the Yahoo message board for years.

[akamaii]

Went back over 7 months and you have not posted once on this stock.

[clearsudden]

Wouldn't bank on that. If they do ever get to report, it might be disastrous.

Who knows.

[akamaii]

That day days ago on 200k volume how much it went up?

[clearsudden]

It's sporadic but it takes a few days to go up quickly. It's been quiet for a year

[akamaii]

Has the volume been this low is this normal

[akamaii]

Triple down this x it's bottom

[clearsudden]

Too long

2-3 years

[akamaii]

How long you been in this stock

[clearsudden]

Can you please ask them why are they so retarded with there reporting.

Thanks

[akamaii]

I'm a block away from office perhaps I should knock knock on they door lol

[clearsudden]

I sent an email to investor relations no reply. They are a year behind in filings

[akamaii]

Watching

[DrShocker]

Too lazy right now for DD. Can anyone else substantiate these claims/facts?

[willlbone]

Might buy around buck fifty.

[svksudupa]

I think ERBA is on the cusp of growth . They are just 3 year old compny with big plans on acquisition and merger. Strong back up by Suresh an entrepreneur the 82% owner of this company. Lots of global spread and incresing account receivables. They need to work on account receivables. Mohan the CEO said in the OneMed their focus will be more on US growth in 2015. Time horizon for merger and folding of all global ERBA units(currently $200M rev) in the next 3 to 5 years. US sales target of $100 to 150 M in the next 3 to 5 years. Consistent profitability is their motto. Immunology and molecular technology appears to be their next target segment. Good source for consistent revenue. Acquisitions in Latin America (Brazil). The best part is the exponential growth on the reagents sales Y over Y. They are planning to grow by selling their instruments cheaply.The new marketing guy seems to have lots of experience. They can become a $500M(Mohan says 1Billion) rev company in 5 years with the added dilution and a total of say 100 million shares .I based it on purchase of all private ERBAs 20% of the $200 revenue+ inventories at a $5 value). If the profits keep growing with increasing margins and consolidation I would guess the stock price will be $15 or more easily in 5 years (based on 3x 500M revenue market cap). Any other meaningful thoughts ?

[Roland Rick Perry]

Overreaction ?

Any thoughts anyone ? Somebody ?

All I here is crickets...

[Roland Rick Perry]

One med video

http://www.onemedmarket.com/#!erba-diagnostics/c20lo

[makeamint]

deja vu here ;)....Have you been able to see to the Mohan video presentation from the OneMed conference last week? The file
keeps coming up corrupt for me, as I would really like to listen
for the growth guidance.
http://www.b2i.us/profiles/investor/CSummary.asp?BzID=2247&Nav=0&LangID=1&s=0&tPName=Profile

[makeamint]

WAKE UP ;)......ERB will report its third quarter 2014 financial results Monday, November 10, 2014 at approximately 7:30 a.m. Eastern Time. ERBA Chief Executive Officer Mohan Gopalkrishnan, will host a management conference call at 9:00 a.m. Eastern Time to discuss the financial results and business developments.

[cybersync]

$ERB 50mda getting ready to cross 200mda

[cybersync]

ERB AH 3.40

[makeamint]

ERBA Diagnostics Schedules Conference Call to Discuss 2014 Second Quarter Financial Results

ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, announced today it will host an earnings call to discuss the Company's second quarter 2014 financial results at 9:00 a.m. EDT (8:00 a.m. CDT) on Tuesday, August 12, 2014.
http://finance.yahoo.com/news/erba-diagnostics-schedules-conference-call-213105973.html

[cybersync]

consolidating ready to go higher

[clearsudden]

Erba Diagnostics Video Presentation July 24th 2014

[clearsudden]

July 26th 2014 video Erba

[cybersync]

ERB

[makeamint]

We should be getting some play here $$$$OON...Status update from the AACC,and Earnings in next couple of weeks and more importantly....VOLUME

[cybersync]

Yes I am.

[makeamint]

ERB 2.58....You still in cyber?

$ERB good day chart ready for a move

[cybersync]

$ERB good day chart ready for a move

[cybersync]

ERB news
http://biz.yahoo.com/e/140521/erb8-k.html
http://finance.yahoo.com/news/erba-diagnostics-inc-receives-510-120000873.html
http://www.theflyonthewall.com/permalinks/entry.php/ERBid2014281/ERB-ERBA-Diagnostics-receives-K-clearance-for-XL-analyzer

[cybersync]

ERB chart bullish break 50sma of 2.02 this low float could fly, volume is increasing and we have a spinning top candle

[pamzion]

Ya better load the boat here!